

Product datasheet for TL308823V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

TRIF (TICAM1) Human shRNA Lentiviral Particle (Locus ID 148022)

Product data:

Product Type: shRNA Lentiviral Particles

Product Name: TRIF (TICAM1) Human shRNA Lentiviral Particle (Locus ID 148022)

Locus ID: 148022

Synonyms: MGC35334; PRVTIRB; TICAM-1; TIR domain-containing adaptor molecule 1; TIR domain

containing adaptor inducing interferon-beta; toll-like receptor adaptor molecule 1; TRIF; TRIF,

PRVTIRB, TICAM-1, MGC35334

Vector: pGFP-C-shLenti (TR30023)

Format: Lentiviral particles

Components: TICAM1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble

control), 0.5 ml each, >10^7 TU/ml.

RefSeq: NM 014261, NM 182919, NM 182919.1, NM 182919.2, NM 182919.3, NM 014261.1,

BC009860, BC035331, BC136556, BC136557, NM 182919.4

UniProt ID: Q8IUC6

Summary: This gene encodes an adaptor protein containing a Toll/interleukin-1 receptor (TIR) homology

domain, which is an intracellular signaling domain that mediates protein-protein interactions between the Toll-like receptors (TLRs) and signal-transduction components. This protein is involved in native immunity against invading pathogens. It specifically interacts with toll-like receptor 3, but not with other TLRs, and this association mediates dsRNA induction of interferon-beta through activation of nuclear factor kappa-B, during an antiviral immune response. Mutations in this gene are associated with encephalopathy, acute, infection-

induced. [provided by RefSeq, Jul 2020]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.







Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).